▎WuXiEdited by Kant Content Team

Today, Johnson & Johnson announced an approximately $14.6 billion acquisition of Intra-Cellular Therapies, a company focused on developing therapies for central nervous system disorders. Eli Lilly and Company announced an acquisition agreement with Scorpion Therapeutics, potentially spending $2.5 billion to acquire a selective PI3Kα inhibitor. GSK announced it will spend $1.15 billion to acquire IDRx. Below, let’s take a look at how these acquisitions will strengthen the three major pharmaceutical companies' presence in specific disease areas.

Approximately $14.6 Billion: Johnson & Johnson Strengthens Its Central Nervous System Disease Pipeline

Johnson & Johnson and Intra-Cellular Therapies announced today that they have reached a definitive agreement under which Johnson & Johnson will acquire Intra-Cellular Therapies for approximately $14.6 billion. Through this acquisition,Johnson & Johnson will acquire Caplyta (lumateperone) from Intra-Cellular Therapies. This is a once-daily oral therapy approved for the treatment of adult schizophrenia, as well as depressive episodes associated with bipolar I or II disorder.In addition, this acquisition also includes a Phase 2 clinical-stage candidate drug, ITI-1284, which is currently being evaluated for its potential in treating generalized anxiety disorder (GAD) and psychosis and agitation associated with Alzheimer's disease. Johnson & Johnson will also gain access to Intra-Cellular Therapies' clinical-stage R&D pipeline.

In December 2024, Intra-Cellular Therapies announced that it had submitted a supplemental New Drug Application (sNDA) to the U.S. FDA, seeking approval for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD). In two global, double-blind, placebo-controlled Phase 3 studies, Caplyta, as an adjunct to antidepressants, demonstrated statistically significant and clinically meaningful improvements in reducing depressive symptoms. The press release noted that if approved,Caplyta is expected to become the first drug approved in the past 15 years for treating MDD and depressive symptoms of bipolar I and II disorders.

$2.5 Billion: Lilly Acquires Potential "Best-in-Class" PI3Kα Inhibitor

Eli Lilly and Company and Scorpion Therapeutics announced today that they have reached a definitive agreement,Lilly to Acquire Scorpion's PI3Kα Inhibitor Program STX-478Scorpion is a biotechnology company focused on developing small-molecule precision oncology therapies.

STX-478 is a once-daily, orally administered mutant-selective PI3Kα inhibitor currently in Phase 1/2 clinical trials for the treatment of breast cancer and other advanced solid tumors. STX-478 is designed to improve treatment outcomes for patients with PI3Kα mutations, which are among the most common drivers of cancer. In preclinical models,STX-478 demonstrates potent activity against multiple PI3Kα mutants while avoiding inhibition of wild-type PI3Kα in normal tissues, thereby overcoming the major limitations of existing PI3Kα pathway drugs. This approach may offer better disease control through deeper pathway inhibition while improving patient tolerability.

$1.15 Billion: GSK Acquires Highly Selective KIT Tyrosine Kinase Inhibitor

GSK and IDRx Announce Agreement: GSK to Acquire IDRx. IDRx is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of gastrointestinal stromal tumors (GIST). Under the terms of the agreement, GSK will pay $1 billion upfront and an additional $150 million in potential milestone payments upon reaching regulatory approval milestones.This acquisition includes IDRx's lead candidate drug IDRX-42, a highly selective KIT tyrosine kinase inhibitor being developed for first-line and second-line treatment of GIST patients.

GISTs usually occur in the gastrointestinal tract, where 80% of cases are caused byKITCaused by gene mutations. About 90% of GIST patients will develop newKITGene mutations often lead to disease recurrence and limited treatment options.

IDRX-42 has demonstrated activity against all key primary and secondary KIT mutants, and is designed to improve treatment outcomes for GIST patients. With its broad mutation coverage and potentially enhanced tolerability due to high selectivity, IDRX-42 has the potential to become a "best-in-class" drug.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is strictly prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.